PF-07062119
- Generic Name
- PF-07062119
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.
Phase 1
Terminated
- Conditions
- Gastrointestinal TumorsColorectal AdenocarcinomasGastric AdenocarcinomasEsophageal Adenocarcinomas
- Interventions
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 79
- Registration Number
- NCT04171141
- Locations
- 🇦🇺
The Royal Melbourne Hospital, Parkville, Victoria, Australia
🇺🇸UCLA Department of Medicine: Hematology-Oncology, Los Angeles, California, United States
🇺🇸UCLA Hematology Oncology - Santa Monica, Santa Monica, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath